$MIRM
Mirum Pharmaceuticals, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022003229 Filed on March 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $12.89M $3.138M $19.14M
YoY Change
Cost Of Revenue $2.424M $1.903M $1.903M
YoY Change
Gross Profit $10.47M $1.235M $17.24M
YoY Change
Gross Profit Margin 81.2% 39.36% 90.06%
Selling, General & Admin $19.12M $19.04M $59.22M
YoY Change 101.67% 163.28% 161.0%
% of Gross Profit 182.61% 1541.3% 343.6%
Research & Development $24.09M $27.78M $131.4M
YoY Change -36.83% -6.58% 61.05%
% of Gross Profit 230.11% 2248.99% 762.56%
Depreciation & Amortization $342.0K $342.0K $595.0K
YoY Change 280.0% 280.0% 95.08%
% of Gross Profit 3.27% 27.69% 3.45%
Operating Expenses $45.63M $46.81M $192.6M
YoY Change -4.17% 26.68% 84.62%
Operating Profit -$32.74M -$45.58M -$173.4M
YoY Change -31.25% 66.27%
Interest Expense -$3.705M -$4.850M -$17.96M
YoY Change 27.76% 2752.94% -1571.8%
% of Operating Profit
Other Income/Expense, Net -$154.0K -$17.00K -$582.0K
YoY Change 862.5% -78.75% 203.13%
Pretax Income -$36.60M $57.56M -$83.95M
YoY Change -27.57% -254.73% -18.7%
Income Tax $11.00K $12.00K $37.00K
% Of Pretax Income 0.02%
Net Earnings -$36.61M $57.55M -$83.99M
YoY Change -27.56% -254.69% -18.67%
Net Earnings / Revenue -283.94% 1833.84% -438.85%
Basic Earnings Per Share -$1.17 -$2.77
Diluted Earnings Per Share -$1.170M $1.884M -$2.770M
COMMON SHARES
Basic Shares Outstanding 31.73M 30.64M 30.32M
Diluted Shares Outstanding 31.30M 30.32M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $139.9M $156.5M $156.5M
YoY Change -34.35% -32.47% -32.47%
Cash & Equivalents $46.27M $31.34M $31.34M
Short-Term Investments $93.64M $125.2M $125.2M
Other Short-Term Assets $5.908M $5.271M $5.271M
YoY Change 28.43% 17.13% 17.13%
Inventory $1.580M $1.513M $1.513M
Prepaid Expenses
Receivables $7.872M $3.267M $3.267M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $155.3M $166.6M $166.6M
YoY Change -28.71% -29.51% -29.53%
LONG-TERM ASSETS
Property, Plant & Equipment $898.0K $981.0K $2.550M
YoY Change -71.03% -24.13% -20.31%
Goodwill
YoY Change
Intangibles $18.48M $18.74M
YoY Change
Long-Term Investments $0.00 $4.983M $4.983M
YoY Change
Other Assets $2.033M $1.786M $101.8M
YoY Change 42.57% 40.41% 7729.69%
Total Long-Term Assets $122.9M $128.1M $128.1M
YoY Change 2666.94% 2736.93% 2745.76%
TOTAL ASSETS
Total Short-Term Assets $155.3M $166.6M $166.6M
Total Long-Term Assets $122.9M $128.1M $128.1M
Total Assets $278.1M $294.7M $294.7M
YoY Change 25.16% 22.33% 22.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.943M $9.166M $9.166M
YoY Change -12.64% 190.89% 186.44%
Accrued Expenses $26.88M $30.72M $31.43M
YoY Change -3.23% 129.09% 124.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.55M $42.60M $42.60M
YoY Change -1.28% 130.72% 130.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.00K $17.00K $131.8M
YoY Change -58.33% -41.38% 162.11%
Total Long-Term Liabilities $10.00K $17.00K $131.8M
YoY Change -58.33% -41.38% 162.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.55M $42.60M $42.60M
Total Long-Term Liabilities $10.00K $17.00K $131.8M
Total Liabilities $169.2M $174.4M $174.4M
YoY Change 91.51% 153.66% 153.55%
SHAREHOLDERS EQUITY
Retained Earnings -$293.8M -$257.2M
YoY Change 31.33% 48.5%
Common Stock $402.8M $377.4M
YoY Change 12.65% 9.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.9M $120.2M $120.2M
YoY Change
Total Liabilities & Shareholders Equity $278.1M $294.7M $294.7M
YoY Change 25.16% 22.33% 22.31%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$36.61M $57.55M -$83.99M
YoY Change -27.56% -254.69% -18.67%
Depreciation, Depletion And Amortization $342.0K $342.0K $595.0K
YoY Change 280.0% 280.0% 95.08%
Cash From Operating Activities -$39.67M -$33.15M -$132.8M
YoY Change 57.35% -8.64% 49.04%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$19.00M $24.00K
YoY Change -100.0% 63243.33% -89.33%
Acquisitions $0.00
YoY Change
Other Investing Activities $36.50M $127.0M $67.57M
YoY Change -211.35% -2681.83% 77.35%
Cash From Investing Activities $36.50M $108.0M $48.55M
YoY Change -211.33% -2282.28% 28.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.10M 615.0K 73.47M
YoY Change 174.55% -99.54% -59.48%
NET CHANGE
Cash From Operating Activities -39.67M -33.15M -132.8M
Cash From Investing Activities 36.50M 108.0M 48.55M
Cash From Financing Activities 18.10M 615.0K 73.47M
Net Change In Cash 14.93M 75.49M -10.75M
YoY Change -129.05% -19.07% -108.26%
FREE CASH FLOW
Cash From Operating Activities -$39.67M -$33.15M -$132.8M
Capital Expenditures $0.00 -$19.00M $24.00K
Free Cash Flow -$39.67M -$14.14M -$132.8M
YoY Change 57.34% -60.98% 48.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
125201000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
89734000
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001759425
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38981
CY2021 dei Entity Registrant Name
EntityRegistrantName
Mirum Pharmaceuticals, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1281555
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
950 Tower Lane, Suite 1050
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
CY2021 dei City Area Code
CityAreaCode
650
CY2021 dei Local Phone Number
LocalPhoneNumber
667-4085
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
MIRM
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Public Float
EntityPublicFloat
300000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31730420
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Irvine, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31340000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142086000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3267000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2021Q4 us-gaap Inventory Net
InventoryNet
1513000
CY2020Q4 us-gaap Inventory Net
InventoryNet
0
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5271000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4530000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
166592000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
236350000
CY2021Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2020Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
0
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
4983000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
981000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1293000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1569000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1949000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18740000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1786000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1272000
CY2021Q4 us-gaap Assets
Assets
294651000
CY2020Q4 us-gaap Assets
Assets
240864000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9166000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3151000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30723000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13411000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
711000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
636000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1996000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1264000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42596000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18462000
CY2021Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
129923000
CY2020Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
47651000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1903000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2627000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
29000
CY2021Q4 us-gaap Liabilities
Liabilities
174439000
CY2020Q4 us-gaap Liabilities
Liabilities
68769000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2020Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30705060
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30582596
CY2021Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
122464
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30032600
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29776544
CY2020Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
256056
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
377403000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345180000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257159000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173171000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-35000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
120212000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294651000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240864000
CY2021 us-gaap Revenues
Revenues
19138000
CY2020 us-gaap Revenues
Revenues
0
CY2021 mirm Cost Of Sales1
CostOfSales1
1903000
CY2020 mirm Cost Of Sales1
CostOfSales1
0
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
131428000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
81605000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59220000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22691000
CY2021 us-gaap Operating Expenses
OperatingExpenses
192551000
CY2020 us-gaap Operating Expenses
OperatingExpenses
104296000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-173413000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-104296000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
366000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
1559000
CY2021 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
17590000
CY2020 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
335000
CY2021 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
732000
CY2020 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-582000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-192000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.77
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12554000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-103270000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.09
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30321722
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25251968
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83988000
CY2020 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-46000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7038000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1254000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23087000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83988000
CY2021 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
118000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
120212000
CY2021 mirm Gain On Sale Of Priority Review Voucher
GainOnSaleOfPriorityReviewVoucher
108000000
CY2020 mirm Gain On Sale Of Priority Review Voucher
GainOnSaleOfPriorityReviewVoucher
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83951000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103264000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83988000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-103270000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-103270000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-117000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-75000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
29000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84106000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103316000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
130349000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
328000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
456000
CY2021 us-gaap Profit Loss
ProfitLoss
-83988000
CY2020 us-gaap Profit Loss
ProfitLoss
-103270000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
23087000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
12554000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
595000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
305000
CY2021 mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
380000
CY2020 mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
318000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
137000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
72000
CY2021 mirm Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
17590000
CY2020 mirm Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
335000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
-732000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
0
CY2021 mirm Gain On Sale Of Priority Review Voucher Net
GainOnSaleOfPriorityReviewVoucherNet
-108000000
CY2020 mirm Gain On Sale Of Priority Review Voucher Net
GainOnSaleOfPriorityReviewVoucherNet
0
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4009000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1827000
CY2021 mirm Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
0
CY2020 mirm Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
94000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-495000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
519000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-954000
CY2021 mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
22655000
CY2020 mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
3683000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-649000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-385000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132758000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89075000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
155600000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
85900000
CY2021 mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
2000000
CY2020 mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
26761000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
198029000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
74562000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
225000
CY2021 mirm Proceeds From Sale Of Priority Review Voucher Net
ProceedsFromSaleOfPriorityReviewVoucherNet
108000000
CY2020 mirm Proceeds From Sale Of Priority Review Voucher Net
ProceedsFromSaleOfPriorityReviewVoucherNet
0
CY2021 mirm Additions To Intangible Assets
AdditionsToIntangibleAssets
-19000000
CY2020 mirm Additions To Intangible Assets
AdditionsToIntangibleAssets
0
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48547000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37874000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6914000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
121087000
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10000000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2098000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
784000
CY2021 mirm Proceeds From Revenue Interest Liability
ProceedsFromRevenueInterestLiability
64575000
CY2020 mirm Proceeds From Revenue Interest Liability
ProceedsFromRevenueInterestLiability
49575000
CY2021 mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
-121000
CY2020 mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
0
CY2021 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
CY2020 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
158000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73466000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
181288000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10746000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
130116000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142086000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11970000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131340000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142086000
CY2021 mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
1018000
CY2020 mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
0
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
11000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
864000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
576000
CY2021 mirm Revenue Interest Liability Issuance Costs Included In Accrued Liabilities
RevenueInterestLiabilityIssuanceCostsIncludedInAccruedLiabilities
0
CY2020 mirm Revenue Interest Liability Issuance Costs Included In Accrued Liabilities
RevenueInterestLiabilityIssuanceCostsIncludedInAccruedLiabilities
229000
CY2021 mirm Deferred Offering Costs Included In Accrued Liabilities
DeferredOfferingCostsIncludedInAccruedLiabilities
0
CY2020 mirm Deferred Offering Costs Included In Accrued Liabilities
DeferredOfferingCostsIncludedInAccruedLiabilities
129000
CY2021 mirm Compound Derivative Liability Related To Revenue Interest Liability
CompoundDerivativeLiabilityRelatedToRevenueInterestLiability
0
CY2020 mirm Compound Derivative Liability Related To Revenue Interest Liability
CompoundDerivativeLiabilityRelatedToRevenueInterestLiability
1264000
CY2021 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257200000
CY2021Q4 mirm Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
261500000
CY2021Q4 mirm Unrestricted Cash Cash Equivalents And Short And Long Term Investments
UnrestrictedCashCashEquivalentsAndShortAndLongTermInvestments
161500000
CY2021 mirm Gain On Sale Of Priority Review Voucher
GainOnSaleOfPriorityReviewVoucher
108000000.0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.28%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.28%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the calculation of estimated rebates for applicable discounts and allowances that are offered within contracts to customers, payors and other third parties, the calculation of the revenue interest liability, effective interest rate and corresponding expense, accrued research and development expenses, the valuation of derivative liabilities and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.28%;font-size:10.0pt;margin-top:10.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, a novel strain of coronavirus, which causes COVID-19, was identified. Due to the rapid and global spread of the virus, on March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. To slow the proliferation of COVID-19, governments have implemented extraordinary measures, which include the mandatory closure of businesses, restrictions on travel and gatherings, and quarantine and physical distancing requirements.</span></p><p style="text-indent:4.28%;font-size:10.0pt;margin-top:10.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no significant estimates contained in the preparation of the Company’s consolidated financial statements or impacts to the Company’s consolidated financial statements for the year ended December 31, 2021 that were directly a result of the COVID-19 pandemic. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31340000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142086000
CY2021Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2020Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131340000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142086000
CY2021 mirm Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P3M
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
700
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
300000
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P18Y
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-260000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
89734000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18740000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1038000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1038000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1038000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1038000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1038000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
13550000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18740000
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12Y
CY2021Q4 us-gaap Inventory Net
InventoryNet
1500000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
9200000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
600000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7086146
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5903227
CY2020Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
1264000
CY2021 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
732000
CY2021Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
258640000
CY2021Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
36000
CY2021Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
258604000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
28420000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
125201000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4983000
CY2021Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
258604000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
229432000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
82000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2020Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
229513000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
139779000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4801000
CY2020Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
229513000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
125201000
CY2021Q4 mirm Held To Maturity Securities Debt Maturities Rolling Year One Through Two Fair Value
HeldToMaturitySecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue
4983000
CY2021Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
130184000
CY2021 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
CY2020 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
856000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
570000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
87000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1513000
CY2021Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
6732000
CY2020Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
3673000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3068000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2157000
CY2021Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
4635000
CY2020Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
2780000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9988000
CY2021Q4 mirm Accrued Collaboration Liabilities Current
AccruedCollaborationLiabilitiesCurrent
6300000
CY2020Q4 mirm Accrued Collaboration Liabilities Current
AccruedCollaborationLiabilitiesCurrent
0
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30723000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13411000
CY2019Q4 mirm Revenue Interest Liability
RevenueInterestLiability
49234000
CY2020 mirm Interest Expense Accrued
InterestExpenseAccrued
335000
CY2020 mirm Debt Issuances Costs Capitalized
DebtIssuancesCostsCapitalized
-654000
CY2020 mirm Debt Discount From Embedded Derivatives
DebtDiscountFromEmbeddedDerivatives
-1264000
CY2020Q4 mirm Revenue Interest Liability
RevenueInterestLiability
47651000
CY2021 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
65000000
CY2021 mirm Interest Expense Accrued
InterestExpenseAccrued
17590000
CY2021 mirm Debt Issuances Costs Capitalized
DebtIssuancesCostsCapitalized
-197000
CY2021 mirm Revenue Interest Payments
RevenueInterestPayments
-121000
CY2021Q4 mirm Revenue Interest Liability
RevenueInterestLiability
129923000
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600
CY2021 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease term is approximately four years with an option to extend the term for one five-year term, which at the time was not reasonably assured of exercise and therefore, not included in the lease term.
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q1 mirm Tenant Improvement Allowance
TenantImprovementAllowance
400000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1600000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2600000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
889000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
918000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
926000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
229000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2962000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
348000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2614000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2020Q3 mirm Maximum Amount Of Sale Covered In Shelf Registration Statement
MaximumAmountOfSaleCoveredInShelfRegistrationStatement
300000000.0
CY2021Q4 mirm Common Stock Aggregate Offering Price Remaining
CommonStockAggregateOfferingPriceRemaining
68400000
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10286323
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8343673
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23016000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12554000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-84217000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-103371000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
266000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
107000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83951000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103264000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
37000000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
6000000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5815000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0132
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0042
CY2021 mirm Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0170
CY2020 mirm Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0089
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0772
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0642
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2841
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2696
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0005
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0001
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31819000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26122000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
18501000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
11294000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4027000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
812000
CY2021Q4 mirm Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
10277000
CY2020Q4 mirm Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
5560000
CY2021Q4 mirm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
543000
CY2020Q4 mirm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
661000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2769000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
70982000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47218000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
319000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
385000
CY2021Q4 mirm Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
138000
CY2020Q4 mirm Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
184000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
457000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
569000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70525000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46649000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
23900000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
27800000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3933000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1490000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
17000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2466000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2460000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6399000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3933000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2020Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0

Files In Submission

Name View Source Status
0000950170-22-003229-index-headers.html Edgar Link pending
0000950170-22-003229-index.html Edgar Link pending
0000950170-22-003229.txt Edgar Link pending
0000950170-22-003229-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img67933938_0.jpg Edgar Link pending
img67933938_1.jpg Edgar Link pending
img67933938_2.jpg Edgar Link pending
img67933938_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
mirm-20211231.htm Edgar Link pending
mirm-20211231.xsd Edgar Link pending
mirm-20211231_cal.xml Edgar Link unprocessable
mirm-20211231_def.xml Edgar Link unprocessable
mirm-20211231_htm.xml Edgar Link completed
mirm-20211231_lab.xml Edgar Link unprocessable
mirm-20211231_pre.xml Edgar Link unprocessable
mirm-ex10_10.htm Edgar Link pending
mirm-ex10_14.htm Edgar Link pending
mirm-ex10_15.htm Edgar Link pending
mirm-ex10_35.htm Edgar Link pending
mirm-ex10_6.htm Edgar Link pending
mirm-ex10_7.htm Edgar Link pending
mirm-ex10_8.htm Edgar Link pending
mirm-ex23_1.htm Edgar Link pending
mirm-ex31_1.htm Edgar Link pending
mirm-ex31_2.htm Edgar Link pending
mirm-ex32_1.htm Edgar Link pending
mirm-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending